Should all patients with diabetes mellitus be started on an antiplatelet regimen?

Should All Diabetics Be Started on Antiplatelet Regimen?

No, not all diabetic patients should be started on antiplatelet therapy—the decision depends critically on whether they need primary versus secondary prevention, with recent evidence showing aspirin should NOT be routinely used for primary prevention in most diabetic patients.

Secondary Prevention: Clear Indication

For diabetic patients with established atherosclerotic cardiovascular disease (ASCVD), aspirin therapy is strongly recommended 1, 2. This includes patients with:

• History of myocardial infarction
• Prior stroke
• Known coronary artery disease
• Peripheral arterial disease
• Post-revascularization procedures

Recommended regimen:

• Aspirin 75-162 mg daily (81 mg is most common in the U.S.) 1, 2
• For aspirin allergy: clopidogrel 75 mg daily 1
• Dual antiplatelet therapy (aspirin + P2Y12 inhibitor) for up to 12 months after acute coronary syndrome 1, 3

The evidence for secondary prevention is robust and unequivocal across all major guidelines.

Primary Prevention: Generally NOT Recommended

The most recent and highest-quality evidence demonstrates that aspirin should NOT be routinely prescribed for primary prevention in diabetic patients 4, 1. This represents a significant shift from older recommendations.

Why the Change?

Recent landmark trials (ASCEND, ARRIVE, ASPREE) published in 2018-2019 fundamentally altered the risk-benefit calculus 1:

• ASCEND trial: While aspirin reduced serious vascular events (OR 0.88), it equally increased major bleeding events (OR 1.29) 1
• ARRIVE trial: No benefit on primary endpoints (HR 0.96), with doubled gastrointestinal bleeding risk (HR 2.11) 1
• ASPREE trial: No cardiovascular benefit (HR 0.95) with 38% increased major hemorrhage (HR 1.38) 1

The bleeding risk may be as high as 5 per 1,000 per year, essentially offsetting any cardiovascular benefit in lower-risk patients 1.

Limited Exception for High-Risk Primary Prevention

Aspirin may be considered (not routinely recommended) in select diabetic patients who meet ALL of the following 1, 2:

• Age ≥50 years
• At least one additional major cardiovascular risk factor:
  • Family history of premature ASCVD
  • Hypertension
  • Dyslipidemia
  • Smoking
  • Chronic kidney disease/albuminuria
• Low bleeding risk (no history of GI bleeding, not elderly >70 years, no anemia, no renal disease)
• 10-year cardiovascular risk >10% 5

Critical caveat: Even in this group, the 2019 ADA guidelines state aspirin "may be considered" but "may generally not be recommended," particularly in adults over 70 years where risk exceeds benefit 1.

Clear Contraindications

Do NOT use aspirin in:

• Age <50 years with no additional risk factors 1, 2
• Age >70 years (bleeding risk exceeds benefit) 1
• Age <21 years (Reye syndrome risk) 6, 7
• Active bleeding or high bleeding risk
• Low cardiovascular risk (10-year risk <5%) 5

Evolution of Guidelines

The European guidelines explicitly state: "Antiplatelet therapy with aspirin is not recommended for people with diabetes who do not have clinical evidence of atherosclerotic disease" (Class III, Level A - Strong recommendation) 4. This is the strongest possible recommendation AGAINST routine use.

The Canadian guidelines similarly conclude: "There is currently no evidence to recommend routine use of aspirin at any dose for the primary prevention of vascular ischemic events in patients with diabetes (Class III, Level A)" 8.

Practical Algorithm

Step 1: Does the patient have established ASCVD (prior MI, stroke, known CAD, PAD)?

• YES → Start aspirin 75-162 mg daily (secondary prevention)
• NO → Proceed to Step 2

Step 2: Is the patient age <50 years with no additional risk factors OR age >70 years?

• YES → Do NOT prescribe aspirin
• NO → Proceed to Step 3

Step 3: Does the patient have ≥1 additional major risk factor AND low bleeding risk?

• YES → Consider aspirin through shared decision-making (emphasize uncertain benefit vs. definite bleeding risk)
• NO → Do NOT prescribe aspirin

Common Pitfalls to Avoid

1. Assuming all diabetics need aspirin: This outdated approach ignores recent high-quality evidence showing harm in low-risk patients
2. Ignoring bleeding risk: Elderly patients, those with renal disease, and those with anemia have substantially elevated bleeding risk that outweighs benefit
3. Using aspirin as a substitute for optimal diabetes management: Glycemic control, blood pressure management, and statin therapy have far stronger evidence for cardiovascular risk reduction 5, 4
4. **Prescribing aspirin in patients <50 years without additional risk factors**: The number needed to treat is prohibitively high (>1000 patients for 1 year to prevent 2 events) 8

The bottom line: Aspirin is for secondary prevention in diabetics with established cardiovascular disease, not a blanket recommendation for all diabetic patients.